2026 Interim report
Filed with HKEX · Stock code 6938 · · 93 pages · English
Summary by 6ix AI
The report includes financial highlights such as revenue, gross profit, and profit or loss figures compared to the previous year. Additionally, it provides insights into the company's research and development focus on oligonucleotide therapeutics and its proprietary delivery technologies. The management discussion outlines the company's strategic direction and advancements in its drug development pipeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Suzhou Ribo Life Science Co. Ltd. on 6ix
Earlier from Suzhou Ribo Life Science
- Next Day Disclosure Return
- Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AI
- Ribo and Boehringer Ingelheim further progress their siRNA program for metabolic dysfunction-associated steatohepatitis (MASH)
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
- Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
Later from Suzhou Ribo Life Science
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - phase i clinical trial application submission of RBD3133 injection for overweight and obesity
- Discloseable and connected transaction acquisition of the remaining 49.71% shareholding in a subsidiary involving the issue of consideration shares under Specific mandate; and proposed change of registered capital and amendments to the articles of association
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Suzhou Ribo Life Science into a list and get an email when it puts out news.
Follow Suzhou Ribo Life Science